Preview Mode Links will not work in preview mode

Oct 15, 2019

Recently there have been attempts by small-to-medium sized pharmaceutical companies to create in-house, integrated platform-DDD (PD3) capabilities. This strategy does not come without risks, but has quietly been implemented to increase drug candidate efficacy/safety and pipeline numbers. In some cases this has resulted...


Oct 8, 2019

Recently there has been some attempt to amalgamate platform technologies within start-up and earlystage drug discovery and development companies to increase drug candidate pipeline numbers. This strategy does not come without risks, but has quietly been implemented by a number of platform-drug discovery and...


Oct 1, 2019

Technology was lauded as the saviour of the drug discovery and development process during the late 1990s. A myriad of independent companies developed and offered ‘innovative’ tools, technologies and platforms to pharmaceutical companies in order to mitigate the time, cost and risk of developing new therapeutic...


Sep 24, 2019

Drug candidates often fail in the clinic for two reasons: they lack efficacy or possess an adverse toxicity profile. These failures can come at a high cost, especially when drug candidates have already progressed along the development pipeline to clinical trial.

Advances in three-dimensional (3D) cell culture systems...


Sep 10, 2019

Plants are stationary soldiers. Rooted to one spot, they are not able to chase nutrients or flee from herbivores and pathogens. So in addition to the basic metabolites they synthesise for their survival, they produce a diverse array of organic compounds through specialised biochemical pathways to counterattack...